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Abstract
Mathematical simulation models for transmission and control of lymphatic filariasis are useful tools
for studying the prospects of lymphatic filariasis elimination. Two simulation models are currently
being used. The first, EPIFIL, is a population-based, deterministic model that simulates average
trends in infection intensity over time. The second, LYMFASIM, is an individual-based, stochastic
model that simulates acquisition and loss of infection for each individual in the simulated population,
taking account of individual characteristics. For settings like Pondicherry (India), where Wuchereria
bancrofti infection is transmitted by Culex quinquefasciatus, the models give similar predictions of the
coverage and number of treatment rounds required to bring microfilaraemia prevalence below a
level of 0.5%. Nevertheless, published estimates of the duration of mass treatment required for
elimination differed, due to the use of different indicators for elimination (EPIFIL: microfilaraemia
prevalence < 0.5% after the last treatment; LYMFASIM: reduction of microfilaraemia prevalence to
zero, within 40 years after the start of mass treatment). The two main challenges for future
modelling work are: 1) quantification and validation of the models for other regions, for
investigation of elimination prospects in situations with other vector-parasite combinations and
endemicity levels than in Pondicherry; 2) application of the models to address a range of
programmatic issues related to the monitoring and evaluation of ongoing control programmes. The
models' usefulness could be enhanced by several extensions; inclusion of different diagnostic tests
and natural history of disease in the models is of particular relevance.
Review
Introduction
Lymphatic filariasis is a mosquito-borne parasitic disease
and an important cause of chronic morbidity in tropical
countries. In 1998, the Global Programme to Eliminate
Lymphatic Filariasis (GPELF) was initiated, aiming at the
worldwide elimination of this parasitic disease as a public
health problem [1]. The main strategy in the global pro-
gramme is to interrupt transmission by annual popula-
tion treatment with antifilarial drugs (diethylcarbamazine
or ivermectin plus albendazole). In addition, morbidity
management should reduce the suffering of patients who
have chronic manifestations. Thirty-nine countries had
started elimination programmes in 2004 [2] and this
number is still growing.
The goal of elimination is ambitious. Past mass treatment
programmes had varying degrees of success. In some areas
transmission was apparently interrupted [3]. In other
areas elimination was not achieved, in spite of long-term
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control programmes [4,5]. How strategic choices, and
operational or biological factors contribute to success or
failure is poorly understood. It is unknown which cover-
age and duration of mass treatment programmes (and
possible additional measures) are required to achieve
elimination and how this depends on the vector and par-
asite strain, endemicity level, and the drugs that are used.
Mathematical models can help to clarify these issues and
application of such models is considered important for
support of GPELF [6].
Mathematical models help us to understand the complex
transmission dynamics of parasitic diseases and are useful
tools for planning and evaluation of control programmes
[7,8]. So-called 'full transmission models', which relate
the acquisition of new infections to the intensity and dis-
tribution of infection in a human population, can be used
to predict the impact of interventions on transmission.
Three such models have been developed for lymphatic
filariasis. The first was developed for the evaluation of a
specific vector control programme [9]. Two more recent
Transmission cycle of lymphatic filariasis with density-dependent mechanisms Figure 1
Transmission cycle of lymphatic filariasis with density-dependent mechanisms. This figure shows the life cycle of Wuchereria 
bancrofti, the main parasitic cause of lymphatic filariasis. The adult worms (macrofilariae) are located in the lymphatic system of 
the human host, where they live for 5–10 years [24, 37]. After mating with male worms, female worms can produce millions of 
microfilariae (mf), which can be found in the bloodstream and have a lifespan of 6–24 months [32]. A mosquito that takes a 
blood meal may engorge some mf. Inside the mosquito, mf develop in about 12 days into L3 stage larvae (L3), which are infec-
tious to humans. When the mosquito takes another blood meal, the L3 can enter the human body and some will migrate to the 
lymphatic system and will develop into mature adult worms. The immature period lasts about 6–12 months [38]. Mf cannot 
develop into adult worms without passing through the developmental stages in the mosquito. Larval development and mos-
quito survival are density-dependent [17, 18]. Two possible mechanisms of acquired immunity are shown [20].Filaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
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models, called EPIFIL [10,11] and LYMFASIM [12], are
more general and are both used to predict the long-term
impact of mass treatment and assess elimination pros-
pects.
This review describes recent progress in the modelling of
lymphatic filariasis, focussing on EPIFIL and LYMFASIM.
After a brief introduction of the processes involved in
transmission and control of lymphatic filariasis, we com-
pare the basic structure of these models and the parameter
quantification. Relevant model predictions are compared
and differences are discussed. We identify remaining chal-
lenges and future research priorities.
Processes in lymphatic filariasis transmission and control
Models for lymphatic filariasis control basically describe
the main biological processes involved in transmission
(Figure 1). For prediction of the effects of intervention on
transmission, it is of particular importance to take account
of density dependence in these processes and to consider
heterogeneities [13-15].
Density dependence is a biological term, which indicates
that the growth rate of a population depends in a non-lin-
ear way on its density. We are most familiar with negative
density-dependent mechanisms that limit the population
growth (i.e. limitation, e.g. reduced survival probabilities
due to crowding). Several of such limiting mechanisms
are known to occur in lymphatic filariasis, particularly in
the parasite development in mosquitoes. For example,
there is a maximum number of microfilariae (mf) that can
be engorged by mosquitoes and the number of L3 larvae
that can survive. Consequently, the proportion of mf that
develop into infectious L3 larvae in Culex quinquefasciatus
does not increase linearly with mf intake, but saturates at
higher levels [16,17]. In addition, the survival probability
of mosquitoes may be reduced with their infection load
[18]. This imposes a natural limit on infection intensity in
mosquitoes. Density dependence may also occur in the
opposite direction, facilitating transmission or popula-
tion growth at higher infection intensities (i.e. facilita-
tion). For example, the probability that a female worm
mates with a male worm increases with higher worm bur-
dens. Further, in some anopheline mosquito species, the
probability that mf develop succesfully into L3 larvae
increases when more mf are engorged [16], although at
higher densities limiting mechanisms may eventually get
the upper hand again. It is unknown to what extent den-
sity dependence, either limitation or facilitation, occurs in
parasite development in humans (establishment, fertility
and survival). Acquired immunity could limit one or
more of these processes [19], but evidence for the opera-
tion of such immunity in lymphatic filariasis is inconclu-
sive [20,21].
Density-dependent mechanisms as described above are
important determinants of the elimination prospects.
Due to such mechanisms, a reduction of one of the trans-
mission determinants (e.g. mosquito biting rate, mf den-
sity in the blood) by control measures does not have a
proportional effect on transmission rates and parasite
abundance. Let us consider the example of limitation in
the number of L3 developing in mosquitoes. When mf
density in the human blood is brought down by mass
treatment, mosquitoes will engorge less mf, but the prob-
ability that these mf develop into L3 increases. Therefore,
the reduction in transmission is less than proportional to
the reduction in mf density. The reverse is true in case of
facilitation, so that the effect on transmission rates is more
than proportional.
The term heterogeneity points at variation between indi-
viduals. Individuals differ for example in genetic back-
ground, nutritional status and behaviour, which may
cause differences in exposure to mosquitoes, susceptibil-
ity to infection, and the survival, maturation and fecun-
dity of parasites. Therefore, individuals may be
predisposed to heavy or light infection, leading to an
aggregated or overdispersed distribution of parasites (with
a few hosts harbouring the majority of the parasites). This
aggregation enhances transmission, because it increases
the probability that female and male worms mate. Indi-
viduals also differ in compliance and responsiveness to
treatment, which is important for the effect of mass treat-
ment [22,23]. Heterogeneity may also occur in the para-
site population, e.g. with respect to the life span and
resistance to treatment.
EPIFIL vs. LYMFASIM: model structure and quantification
The two available models for lymphatic filariasis trans-
mission and control, EPIFIL and LYMFASIM, mainly differ
in the amount of detail included. Specific variants of both
models have been developed for Wuchereria bancrofti
transmitted by Culex quinquefasciatus, using data from an
integrated vector management control programme that
was carried out in Pondicherry, India, from 1981 to 1985
[11,24]. These 'Pondicherry model variants' have been
used for prediction. They are described below.
EPIFIL
EPIFIL simulates the average course of infection over age
and time in a human population. The age-structure of the
population is fixed, but its size is unspecified. Limitation
in the transmission of infection by culicine mosquitoes is
taken into account: the number of infectious L3 larvae
that can develop in mosquitoes saturates at higher mf
intensities. Acquired immunity is included as a second
limiting mechanism: it is triggered by incoming L3 larvae
and reduces the probability that new larvae develop into
adult worms. The model takes account of heterogeneityFilaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
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that is introduced by age-related variation in exposure to
mosquitoes: i.e. the exposure increases with age, until a
maximum level is reached at the age of 9 years. A prede-
termined relationship between mf prevalence and inten-
sity is used to translate predicted mf intensity levels into
mf prevalences. The model can be used to simulate the
impact of vector control, assuming that control measures
reduce the mosquito biting rate. The effects of mass treat-
ment can be simulated, assuming that a proportion of the
population is treated with a drug with pre-specified effi-
cacy; drugs may kill part of the present mf and adult worm
and may reduce the mf production rate per adult worm.
The design of this population-based model is based on a
general differential equation framework describing the
dynamics of macroparasitic infections [13,19,25]. The
model is deterministic, meaning that simulation output is
always the same with fixed input specifications.
LYMFASIM
LYMFASIM simulates the acquisition and loss of worms
over age and time in a discrete number of human individ-
uals, using stochastic microsimulation. Individuals inter-
act through biting mosquitoes and together they form a
dynamic population, of which the size and age-structure
may change over time. Like EPIFIL, LYMFASIM takes
account of limitation in the proportion of engorged mf
that develops into L3 larvae inside the mosquito and of
acquired immunity in human hosts. Two model variants
were developed for Pondicherry, which differed with
respect to the type of acquired immunity: 'anti-L3' immu-
nity is triggered by incoming L3 larvae and reduces the
probability of successful adult worm establishment; 'anti-
fecundity' immunity is triggered by the presence of adult
worms and reduces the rate of mf production by female
worms. By considering individual worms in individual
hosts, the model inherently takes account of the declining
mating probability of female and male worms with lower
average infection intensities. Several sources of heteroge-
neity are considered in this model. This includes age-vari-
ation in exposure: exposure increases until a maximum is
reached at about 20 years of age. Other factors contribut-
ing to heterogeneity are between-person variation in
exposure (not age-related), and variation in inclination to
Table 1: Quantification of several key biological parameters in the EPIFIL and LYMFASIM model variants for Pondicherry, where 
Wuchereria bancrofti is transmitted by Culex quinquefasciatus. Values in bold-face were estimated indirectly by fitting the model 
outcomes to observed epidemiological data; other values were quantified directly from literature, theory, and analysis of local data
Parameter EPIFIL LYMFASIM
Anti-L3 immunity Anti-fecundity immunity
Parasite lifecycle
Average adult worm life span in years  8 a 10.2 b 11.8 b
Average mf life span in months  10 a 10 c 10 c
Premature period in months - 8 8
Exposure variation by age
Exposure at age zero as fraction of maximum exposure 0 0.26 0.40
Age in years at which maximum exposure is achieved 9 19.1 21.3
Density dependence in mosquitoes
Maximum number of L3 larvae that can develop in mosquitoes at high mf 
intensities
6 d 6.6 e 6.6 e
Acquired immunity
Duration of acquired immunity in years lifelong 9.6 f 11.2 f
Other parameters
Monthly biting rate 5760 2200 2200
Proportion of L3 larvae in mosquitoes that enters the human host when a 
mosquito bites
0.414*0.32 = 0.13 0.1 0.1
Proportion of inoculated L3 larvae that develops successfully into adult 
worms (x10-3)
0.113 1.03 g 0.42
Mf production per worm 2 0.61 h 4.03 h, i
- Not considered in the model; mf, microfilaria.
a Assuming an exponential distribution.
b Assuming a Weibull distribution with shape parameter α = 2.
c Assuming an exponential distribution, approximated with discrete time steps.
d Exponential saturating function with initial increase from zero = 0.047.
e Hyperbolic saturating function with initial increase from zero = 0.09.
f Period in which the strength of the immune response is halved in the absence of boosting.
g In the absence of anti-L3 immunity.
h In the presence of at least 1 male worm, scaled to the number of mf per 20 µl peripheral blood.
i In the absence of anti-fecundity immunity.Filaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
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participate in treatment programmes, the response to
treatment, and the ability to develop immune responses.
Parasites may vary with respect to their life span (about 10
years on average). Individual mf intensities are translated
into the number of mf that would be counted in a 20 µl
blood smear, taking account of random variability in
these counts and reduced sensitivity of diagnostic tests at
lower mf densities. The mf prevalence and mean mf inten-
sity can be directly calculated from the smear counts,
using data from all simulated individuals or specific sub-
groups. Similar to EPIFIL, LYMFASIM can simulate the
impact of vector control by assuming that it reduces the
mosquito biting rate. The model can simulate mass or
selective treatment. In the first case, treatment is given to
part of the of individuals, irrespective of their infection
status; in the latter case, treatment is given only to a pro-
portion of mf positives. Treatment of an individual may
kill a proportion of mf and worms and may temporarily
or permanently reduce the fertility of female worms.
Treatment effects may vary between individuals.
This individual-based model uses the technique of sto-
chastic microsimulation [26], which was earlier applied in
the modelling of onchocerciasis transmission and control
[27]. The stochastic nature of the model implies that there
is variation in simulation outcomes, even if input specifi-
cations are exactly the same.
Parameter values
Table 1 gives the quantification of key biological model
parameters. Both models were quantified for Pondicherry,
but several assumptions were different. For example, EPI-
FIL quantified parameters for the adult worm lifespan,
age-variation in exposure and the mf production per
worm using information from literature and local data.
LYMFASIM estimated these parameters by fitting the
model to observed epidemiological data and arrived at
somewhat different values. The quantification of the
monthly biting rate was based on local data in both mod-
els, but it was much higher in EPIFIL than in LYMFASIM
(5760 vs. 2200). EPIFIL's quantification was based on
weekly mosquito catches that had been carried out in sev-
eral sites in Pondicherry during the first few hours of the
night. LYMFASIM's quantification was based on data from
one single site where all night mosquito catches had been
carried out. To compensate for the higher biting rate in
EPIFIL, a lower value needed to be estimated for the pro-
portion of inoculated L3 larvae that develops successfully
into adult worms.
Both models accurately mimicked epidemiological data
from Pondicherry even though different assumptions
were made. Figure 2 illustrates the good fit of both models
to the precontrol (1981) data from Pondicherry.
EPIFIL vs. LYMFASIM: predictions
Both EPIFIL and LYMFASIM have been used to predict the
impact of control measures and assess prospects for elim-
ination by mass treatment [28-31]. We focus here on
model predictions of the coverage and duration of annual
mass treatment programmes required for elimination. All
published predictions were based on the Pondicherry var-
iants of the models, although acquired immunity was left
out of the model in the EPIFIL predictions. LYMFASIM's
predictions were based on the models with anti-L3 or
anti-fecundity immunity, with a population size of about
3000–4500 individuals.
Comparison of model predictions of microfilaraemia preva- lence by age with observed data, before the start of vector  control (1981) in Pondicherry, India Figure 2
Comparison of model predictions of microfilaraemia preva-
lence by age with observed data, before the start of vector 
control (1981) in Pondicherry, India. (A) LYMFASIM predic-
tions for models with anti-L3 immunity (solid line), anti-
fecundity immunity (dashed line), and a model variant with-
out immunity (dot-dashed line); the latter model did not fit 
the data and was therefore rejected. Source: [24]. (B) EPIFIL 
predictions of a model with acquired immunity. Source: [11]. 
Symbols in both graphs indicate the observed prevalence lev-
els with corresponding confidence intervals.
0
2
4
6
8
10
12
14
16
0 1 02 03 04 05 06 07 0
Age (years)
M
f
 
p
r
e
v
a
l
e
n
c
e
 
i
n
 
1
9
8
1
 
(
%
)
0
2
4
6
8
10
12
14
16
18
0 1 02 03 04 05 06 07 0
Age (years)
M
f
 
p
r
e
v
a
l
e
n
c
e
 
i
n
 
1
9
8
1
 
(
%
)
A
BFilaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
Page 6 of 10
(page number not for citation purposes)
From the predictions of both models we can conclude
that it is possible to eliminate lymphatic filariasis by
yearly mass treatment, but that the number of treatment
rounds largely depends on coverage, precontrol mf preva-
lence and the macrofilaricidal effects of drugs. This is illus-
trated in Tables 2 and 3, and Figure 3. In many situations,
the predicted number of yearly treatment rounds required
for elimination was higher than 4 to 6, which was hoped
to be sufficient when GPELF was initiated. As an alterna-
tive to longer programmes, one might consider more fre-
quent mass treatment (e.g. half-yearly) or the additional
application of vector control (Figure 4).
The predictions for Pondicherry-like situations indicate
that elimination can be achieved within a reasonable
timeframe. In fact, the required time period is shorter than
the mean adult worm lifespan. This is possible, because
the antifilarial drugs are thought to have strong macrofila-
ricidal or sterilizing effect [23,32-34]. Moreover, not all
worms need to be killed or sterilized in order to achieve
elimination. The prevalence just needs to be brought
under a threshold or breakpoint level, below which the
acquisition rate of new worms is lower than the death rate
of existing worms (by treatment or natural death), so that
the worm population will eventually die out. Clearly, the
quantitative predictions should be interpreted with some
care. Achieving elimination would for example be more
difficult, if the macrofilaricidal effects of treatment are
lower, if the adult worms live longer, if there is stronger
aggregation of worm-burdens, or if density-dependent
mechanisms operate that enhance parasite transmission
at low infection intensities. In spite of these uncertainties,
the predictions give important information on the deter-
minants of elimination.
The predictions of EPIFIL and LYMFASIM cannot be com-
pared directly, because the original publications reported
results for different treatment regimens, with different
assumptions on efficacy of the drugs, and different pre-
control mf prevalence levels. Further, different criteria for
elimination were used: in EPIFIL elimination was
assumed to occur if the mf prevalence after treatment was
below 0.5%; in LYMFASIM elimination was defined as a
zero mf prevalence 40 years after the start of control in
99% of the runs. To allow better comparison of the mod-
els, we did a series of additional simulations with LYM-
FASIM for mass treatment with the combination of
diethylcarbamazine plus albendazole, using the same
assumptions on drug-efficacy and the same criterion for
elimination as in published EPIFIL predictions (Table 3).
The two models come to comparable conclusions regard-
ing the number of treatment rounds required to bring mf
prevalence below 0.5%, although LYMFASIM's predic-
tions are slightly more optimistic than EPIFIL's at higher
coverage levels. This finding of nearly equal predictions is
not straightforward. The LYMFASIM model contains sev-
eral assumptions and mechanisms, which, relative to EPI-
FIL, limit the impact of the intervention on transmission:
1) a longer adult worm life span (10 vs. 8 years); 2)
acquired immunity; 3) heterogeneities in exposure to
mosquitoes, in compliance to mass treatment, and in
adult worm life span. However, the limiting effect of these
assumptions and mechanisms on the impact of mass
treatment is apparently counteracted by the enhancing
effect of a reduced mating probability of worms at lower
average worm burdens in LYMFASIM.
Criteria for elimination
The choice of elimination criterion influences predictions
of the efforts required for elimination. EPIFIL's predic-
tions were based on the assumption that transmission will
not continue when the mf prevalence falls below 0.5%.
The choice for this threshold is somewhat arbitrary in the
absence of evidence from the field. LYMFASIM's predic-
tions were based on the eventual reduction of mf preva-
lence to zero (40 years after the start of control) in 99% of
the simulation runs and depend strongly on the model's
accurate reflection of transmission dynamics at low infec-
tion levels. It is interesting to investigate the relationship
Table 2: LYMFASIM predictions of the number of annual mass drug treatment rounds required to achieve elimination in an area like 
Pondicherry, with 99% probability. Results are shown for four different drugs or drug combinations and two coverage levels. 
Predictions are based on the anti-L3 variant of the model for Pondicherry, with a precontrol microfilaraemia prevalence of 8.5%. 
Elimination is defined as zero microfilaraemia prevalence 40 years after the start of treatment. Source: [31]
Assumed treatment effects (proportion killed) Predicted number of rounds for elimination, with 
coverage
Drug(s) adult worms microfilariae 65% 80%
Ivermectin + albendazole 35% 100% 10 6
Diethylcarbamazine 50% 70% 8 5
Diethylcarbamazine + 
albendazole
65% 70% 6 4
Doxycycline 80% 0% 6 4Filaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
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between the outcomes of the two models and the
employed elimination criteria. See Table 3.
Let's consider the situation with a precontrol mf preva-
lence of 10% and 70% coverage per treatment round.
Both LYMFASIM and EPIFIL predicted that 8 rounds of
mass treatment were sufficient to bring the average mf
prevalence below 0.5%. For LYMFASIM, this conclusion
was based on the average trend in 100 runs, but there was
variation between the runs. The precontrol mf prevalence
was 10% on average, but varied between runs (5th – 95th
percentile (p5 – p95): 8.8% – 11.4%). The post-treatment
mf prevalence (1 year after the 8th treatment) was 0.39%
on average, with p5 – p95 = 0.25% – 0.59%. The 0.5%
threshold was reached in 86/100 runs, but elimination
(zero mf prevalence 40 years after the start of control) was
only found in 79 of these 86 runs. The 0.5% threshold was
not reached in 14/100 runs, but elimination occurred nev-
ertheless in 8. Overall, elimination was achieved in 87%
of the runs in this example. One or two extra rounds of
mass treatment would be required to be 99% certain of
elimination.
The numbers are much less favourable in the simulations
with 60% coverage, so that the extra number of treatment
rounds required to be 99% certain of elimination would
be larger. More extensive simulation studies are required
to study how the threshold mf prevalence level, below
which elimination almost always occur, depends on local
transmission dynamics and mosquito biting rates, immi-
gration of parasite carriers or invasion of infected mosqui-
toes, heterogeneities and population size.
Challenges in application of models for support of GPELF
The published model predictions are helpful in planning
and design of elimination programmes. However, major
challenges remain if modelling is to be used more widely
for decision support in GPELF. Firstly, the models need to
be quantified and validated for regions with different
transmission dynamics. Secondly, a wide range of pro-
grammatic issues remains to be addressed.
Quantification and validation of models for other regions
The first major challenge lies in the quantification and val-
idation of model variants for different regions. The dis-
cussed models were both quantified for transmission of
W. bancrofti by Culex quinquefasciatus and tested against
data from Pondicherry [11,24]. Predictions for Pon-
dicherry cannot simply be generalized to other areas,
because transmission dynamics and therefore also elimi-
nation prospects are different due to different vector-par-
asite combinations and endemicity levels. Region-specific
model variants are required.
The development of new model variants requires region-
specific data. Although the value of some parameters can
be assumed to be independent of the area of interest, sev-
eral others must be requantified. Because density depend-
Table 3: EPIFIL and LYMFASIM predictions of the number of yearly mass treatment rounds that is required to reach a 0.5% 
microfilaraemia prevalence threshold. Results are shown for mass treatment with a combination diethylcarbamazine plus 
albendazole, and for various endemicity and coverage levels. The combination treatment is assumed to kill 55% of all adult worms and 
95% of the microfilariae, and to interrupt the microfilaria production for 6 months. EPIFIL's predictions were made with a model 
without acquired immunity. LYMFASIM predictions, from the model with anti-L3 immunity, were added for comparison for an 
average pretreatment microfilaraemia prevalence of 10%. Details of the variability between LYMFASIM runs are included in the lower 
part of the table. The EPIFIL predictions were reprinted from [28], with permission from Elsevier
Coverage
Pretreatment mf prevalence 60% 70% 80% 90%
EPIFIL
2 . 5 % 7654
5 % 9765
1 0 % 1 0 876
1 5 % 1 2 987
LYMFASIM a
10% (p5 – p95: 8.8% – 11.4%) 10 8 6 5
Details of the 100 simulation runs on which the LYMFASIM 
estimations were based:
Average mf prevalence, 1 year after last treatment round 
(p5 – p95)
0.49 (0.29–0.73) 0.39 (0.25–0.58) 0.42 (0.24–0.64) 0.33 (0.22–0.47)
Number of runs (%) with zero mf prevalence 40 years 
after start of treatment, out of the total number that
- had achieved the 0.5% threshold 35/51 (69%) 79/86 (92%) 62/70 (89%) 90/97 (93%)
- had NOT achieved the 0.5% threshold 16/49 (33%) 8/14 (57%) 18/30 (60%) 1/3 (33%)
a Based on the average trend in microfilaraemia prevalence of 100 simulation runs.Filaria Journal 2006, 5:5 http://www.filariajournal.com/content/5/1/5
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ence in the relationship between mf density in the human
blood and the number of L3 larvae developing in mosqui-
toes strongly determines elimination prospects, accurate
quantification of this relationship is particularly impor-
tant. Unfortunately, though, few data are available for the
different mosquito species that can transmit the infection
[35]. Especially for the anopheline mosquito species,
which are responsible for transmission in large parts of
Africa, more field research is needed. Data on mosquito
biting rates and heterogeneity in exposure are similarly
important and difficult to find.
It is crucial to test the validity of new model variants
against epidemiological data. The models reflect current
knowledge of the biology of infection, but some uncer-
tainty remains in the model structure (e.g. is there density
dependence in parasite development in the human host
or not?) and the quantification of specific model parame-
ters (e.g. parasite life span). It is therefore crucial to con-
tinue testing the validity of existing and new model
variants against epidemiological data. Different types of
data help to test different parts of the model. For example,
age-specific data on infection prevalence and intensity
may help to determine the role of acquired immunity and
age-related processes [36]. Epidemiological trends during
vector control are especially informative on the adult
worm life span [24,37]. Trends during mass treatment
may give information on the effects of drugs on worm sur-
vival and productivity. And trends after cessation of con-
trol may help to determine whether density-dependent
mechanisms have appropriately been included in the
model. Such tests may lead to adaptation of the model
structure or parameter quantifications.
Some work has already been done to prepare models for
use in other areas. The LYMFASIM model has been
applied to age-patterns observed in an area in South-East
India that has the same vector-parasite combination and
presumably the same transmission dynamics as Pon-
dicherry. This led to the development of new model vari-
ants with less strong or no immunity (Subramanian,
unpublished data). EPIFIL was also tested against data
from this area to test whether the model could match
observed trends during mass treatment with current
assumptions regarding efficacy of drugs and local trans-
mission dynamics [28]. LYMFASIM is currently being
adapted for use in Africa (Stolk, unpublished data).
Programmatic issues to be addressed
The second major challenge for lymphatic filariasis mod-
els lies in their application: several programmatic issues
remain to be addressed.
So far, the models have been used to estimate the number
of treatment rounds required for elimination and to
examine the benefit of additional measures in specific sit-
uations. This work needs to be extended to determine
more extensively where and when additional measures
are required, and which measures are most cost-effective.
Outcomes will be helpful to develop more specific guide-
lines for elimination programmes.
Besides these strategic issues, several urgent monitoring
and evaluation issues need to be addressed. Any elimina-
tion programme faces the following questions: is the pro-
gramme on track towards elimination or is programme
adjustment required? Can we safely stop mass treatment
without a risk of recrudescence? To better address these
issues, the lymphatic filariasis transmission models
should be extended with newer diagnostic tools. Most
important is inclusion of the card test for antigen detec-
tion, which is widely used in the monitoring and surveil-
lance of ongoing control programmes. This will help in
the development of more precise criteria for when to stop
mass treatment and how to monitor after cessation of
control. It will also allow better calibration of the model
to local situations, by taking better account of earlier
achieved reduction in mf prevalence and intensity. This,
in turn, will improve the accuracy of predictions for a spe-
cific situation. Other extensions of the model may also
have to be considered, such as immigration of parasite
LYMFASIM predictions of the coverage and number of yearly  mass treatment rounds with ivermectin that are required for  lymphatic filariasis elimination in Pondicherry, India Figure 3
LYMFASIM predictions of the coverage and number of yearly 
mass treatment rounds with ivermectin that are required for 
lymphatic filariasis elimination in Pondicherry, India. Precon-
trol microfilaraemia prevalence was assumed to be 8.5%. 
Elimination was said to occur if zero microfilaraemia preva-
lence is reached 40 years after the start of treatment, with 
99% probability. A single treatment with ivermectin (200 µg/
kg) was assumed to sterilize 77% of female worms perma-
nently and to kill all microfilariae. Results are shown for two 
variants of the LYMFASIM model for Pondicherry, differing 
with respect to the assumed immune mechanism (solid line – 
anti-L3 immunity; broken line – anti-fecundity immunity). 
Source: [30].
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carriers or invasion of infected mosquitoes or the develop-
ment of resistance to available drugs.
Although discussion until now focused on the elimina-
tion of transmission, this goal may be too ambitious for
some areas. The focus may shift to reducing the public
health problem without explicitly aiming at eliminating
infection. To address this with the models, more attention
is required for the development of disease. Simple mech-
anisms of disease development are included in both mod-
els, but natural history of disease has received little
attention in published work until now.
Conclusion
Important advances have been made in the modelling of
lymphatic filariasis transmission and control. However,
with the rapidly expanding Global Programme to Elimi-
nate Lymphatic Filariasis there is increasing demand for
model-based support of decision-making. Huge chal-
lenges remain: models need to be quantified and vali-
dated for specific regions and a wide range of
programmatic issues remain to be addressed. The models'
usefulness could be enhanced by several extensions; inclu-
sion of different diagnostic tests and natural history of dis-
ease in the models is of particular relevance. A close link
between modellers and elimination programmes is cru-
cial for successful prediction of the impact of lymphatic
filariasis elimination programmes: the models can be
improved based on new data collected for evaluation of
the elimination programmes, while the programmes can
benefit from more precise guidelines and predictions that
are specific for the local situation concerned.
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